Buy Now
Oligonucleotide Synthesis Market Size, Share, Growth & Industry Analysis, By Product (Oligonucleotide, Reagents, Equipment), By Type (Custom Oligos, Predesigned Oligos), By Application (Therapeutic, Diagnostics), By End-user (Hospitals, Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others), and Regional Analysis, 2025-2032
Pages: 180 | Base Year: 2024 | Release: May 2025 | Author: Versha V.
The market focuses on the custom production of short DNA or RNA sequences used in biotechnology, pharmaceuticals, diagnostics, and research. These synthetic oligos support applications such as gene editing, molecular diagnostics, and therapeutic development.
The market encompasses suppliers and platforms involved in the design, manufacturing, and distribution of high-quality oligonucleotide products. The report outlines the primary drivers of market growth, along with an in-depth analysis of emerging trends and evolving regulatory frameworks shaping the industry's trajectory.
The global oligonucleotide synthesis market size was valued at USD 4.60 billion in 2024 and is projected to grow from USD 5.52 billion in 2025 to USD 19.71 billion by 2032, exhibiting a CAGR of 19.92% during the forecast period.
The market is experiencing growth due to increasing therapeutic applications, particularly in cancer and genetic diseases. Advancements in oligonucleotide-drug conjugates (ODCs) enhance drug targeting and efficacy, driving demand for specialized synthesis solutions, especially in RNAi-based cancer therapies.
Major companies operating in the oligonucleotide synthesis industry are DH Life Sciences, LLC., Eurofins Scientific, KANEKA CORPORATION, Twist Bioscience, Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., LGC Biosearch Technologies Maravai LifeSciences, GenScript, Sarepta Therapeutics, Inc, Novartis AG, Merck KGaA, Azenta US Inc., and AstraZeneca.
The market is being driven by the growing demand for personalized medicine. As treatments are increasingly tailored to individual genetic profiles, the need for precise, patient-specific oligonucleotides continues to rise.
Advancements in genomic technologies and the proliferation of gene therapies have further accelerated this demand, opening new opportunities for oligonucleotide-based solutions in previously untapped therapeutic areas. Custom oligo synthesis plays a crucial role in developing these targeted therapies, propelling market growth and boosting innovation in the biopharmaceutical industry.
Market Driver
Growing Use of Oligonucleotides in Therapeutics
The market is driven by increasing therapeutic applications of oligonucleotides, which enable targeted modulation of gene expression, splicing, and protein production. Their ability to address previously untreatable genetic targets supports development across indications such as cancer, genetic diseases, and viral infections.
Advances in nucleic acid chemistry and delivery technologies are improving efficacy and safety profiles while growing regulatory support is accelerating clinical adoption. These factors are creating sustained demand for scalable, high-quality oligonucleotide synthesis to support drug development pipelines.
Market Challenge
Technical Difficulties in Synthesizing Long Oligonucleotides
Synthesizing long oligonucleotides presents a significant challenge in the oligonucleotide synthesis market due to issues such as low yield, increased error rates, and higher costs. The complexity of maintaining high fidelity during the synthesis of longer sequences affects their viability for advanced therapeutic applications, such as gene editing and RNA therapies.
Companies are addressing this by investing in innovative synthesis technologies, like improved solid-phase synthesis methods and error-correction algorithms. Additionally, advancements in automated platforms and continuous flow reactors are improving efficiency and scalability. Market players are also focusing on optimizing chemical modifications to enhance stability and reduce errors in long oligos.
Market Trend
Advancement in Oligonucleotide-Drug Conjugates
The market is witnessing a significant trend in the advancement of Oligonucleotide-Drug Conjugates (ODCs). These innovative therapeutics combine oligonucleotides with small molecules or antibodies, enhancing drug targeting, efficacy, and overcoming resistance.
Recent breakthroughs in ODC platforms have shown strong antitumor activity, including in pancreatic cancer models, by improving potency and reducing toxicity. This trend is fueling the need for specialized oligonucleotide synthesis solutions, particularly in RNAi-based cancer therapies.
|
Segmentation |
Details |
|
By Product |
Oligonucleotide, Reagents, Equipment |
|
By Type |
Custom Oligos, Predesigned Oligos |
|
By Application |
Therapeutic, Diagnostics, Research(PCR, Sequencing, Others), Others |
|
By End-user |
Hospitals, Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others |
|
By Region |
North America: U.S., Canada, Mexico |
|
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
|
Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
|
South America: Brazil, Argentina, Rest of South America |
Market Segmentation:
Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
North America oligonucleotide synthesis market share stood at around 34.07% in 2024 in the market, with a valuation of USD 1.57 billion. North America holds a dominant position in the market due to its early adoption of advanced enzymatic synthesis technologies, enabling efficient and scalable production of RNA-based therapeutics.
The region benefits from a strong infrastructure for biotech innovation, extensive clinical research activity, and a high concentration of industry experts. These factors support the rapid integration of novel manufacturing methods, positioning North America at the forefront of oligonucleotide-based drug development and commercialization across various therapeutic applications.
Asia Pacific is poised for significant growth at a robust CAGR of 20.93% over the forecast period. The oligonucleotide synthesis industry in Asia Pacific is experiencing growth due to increasing regional investment in local manufacturing capabilities, which enhances self-sufficiency and reduces reliance on imports.
The establishment of advanced synthesis facilities supports domestic production of diagnostic and therapeutic oligonucleotides, aligning with national healthcare initiatives.
This shift is driving market growth by enabling faster regulatory approvals, lowering production costs, and expanding access to advanced molecular diagnostic tools across emerging markets. These developments are strengthening Asia Pacific's position in global biopharmaceutical and diagnostic supply chains.
Key players in the oligonucleotide synthesis market are adopting strategies such as mergers and acquisitions, and new product launches to accelerate market growth. Companies are actively acquiring smaller players to enhance their technological capabilities and expand market presence.
Additionally, firms are introducing innovative oligonucleotide-based solutions, focusing on new therapeutic applications and diagnostic tools. These strategic actions are driving competition and enabling key players to capture a larger share of the global market while supporting the broader adoption of these technologies across clinical and research settings.
Recent Developments (New Product Launch)
